Mediclin stock: fair value
MED.DEThe fair value of Mediclin under our model is $20.66, the price is 71% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $15.89 and expensive above $29.51 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $27.09 (cash-flow model) and $14.23 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.8%. At 8.8% the fair value would be $18.61, at 6.8% it would be $23.58.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 2.1%. Discounted at 7.8% (government bond yield 2.1% plus beta 1.35 times a risk premium of 4.2%); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $27.09 per share: free cash flow for the next ten years, each year discounted to today at 7.8%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 7.8%) |
|---|---|---|---|---|
| 2026 | $66.82M | extrapolated at 7.1% | 0.9273 | $61.96M |
| 2027 | $70.57M | extrapolated at 5.6% | 0.8599 | $60.68M |
| 2028 | $73.8M | extrapolated at 4.6% | 0.7974 | $58.85M |
| 2029 | $76.63M | extrapolated at 3.8% | 0.7395 | $56.67M |
| 2030 | $79.18M | extrapolated at 3.3% | 0.6857 | $54.3M |
| 2031 | $81.54M | extrapolated at 3.0% | 0.6359 | $51.85M |
| 2032 | $83.76M | extrapolated at 2.7% | 0.5897 | $49.39M |
| 2033 | $85.89M | extrapolated at 2.6% | 0.5468 | $46.97M |
| 2034 | $87.98M | extrapolated at 2.4% | 0.5071 | $44.61M |
| 2035 | $90.03M | extrapolated at 2.3% | 0.4702 | $42.34M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $527.6M |
| Terminal value: cash flow 2035 × (1 + 2.1%) / (7.8% − 2.1%) | $1.61B |
| Present value of terminal value (× 0.4702) | $758.93M |
| Equity value (sum plus present value of terminal value) | $1.29B |
| Shares (diluted) | 47.50M |
| Value per share (equity value divided by shares) | $27.09 |
| Earnings per share, last twelve months | $0.72 |
| × 19.6 (industry P/E) | $14.23 |
| Fair value (average of both parts) | $20.66 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Apr 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.